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Abstract
Background and purpose: Metastatic renal cell carcinoma (MRCC) has a poor prognosis with
a median overall survival of about one year. Since only a minority of patients experienced
therapeutic benefit to current treatments, several studies have attempted to identify factors that
may have an impact on response and survival. Cytokines play a crucial role in the host's immune
response by regulating the development and function of a lot of biological compartments.
Nevertheless, available data on basal cytokine levels in MRCC are very few and no clear profile of
serum cytokines has been identified yet in these patients population. Thus, determining the levels
of cytokines in MRCC could not only help in understanding the biological mechanisms of the tumor
growth, but also in evaluating if different cytokine profiles are correlated with particular clinical
behaviors.
Materials and methods: In 144 healthy donors and 55 MRCC treated with subcutaneous IL-2-
based regimens, we analysed a panel of basal cytokines particularly involved in the neoplastic
progression (IL-1beta, IL-6, IL-8, IL-10, IL-12, alpha-TNF) and C-reactive protein (CRP) in order to
compare their levels in the two groups, and to verify their impact on patient response and survival.
We first compared cytokines levels in patients population and healthy donors. Than, in definite
patients group, univariate and multivariate analyses were performed to evaluate the correlation
existing between each factor considered and clinical outcomes. For these analyses, baseline values
were included as dichotomous variables using the median values (above and below) of control
group.
Results: In general, higher levels of cytokines were found in patients with respect to those of
healthy donors, both in term of percentage of undetectable levels or median values. The impact on
response was insignificant, except for higher levels of CRP that were strongly correlated with a
worse response (p < 0.001). Within the patients groups, a worse survival was associated with
higher values of CRP (8 vs 31 months, p = 0.0000), IL-6 (9 vs 25 months, p = 0.0295), and IL-8 (9
vs 17 months, p = 0.0371). Conversely, higher levels of IL-12 were associated with a better survival
(25 vs 15 months, months p = 0.0882). A correlation was found between CRP and IL-6 (p = 0.009)
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and between CRP and IL-10 (p = 0.038). After multivariate analysis only CRP (p = 0.0035) and IL-
12 (p = 0.0371) maintained an independent impact on survival, while IL-6 showed a borderline value
(p = 0.0792).
Conclusion: Higher cytokines levels characterize patients population with respect to healthy
donors. Moreover, higher basal level of some immunosuppressive cytokines (CRP, IL-6, IL-8) result
correlated with a poorer survival, whereas higher levels of IL-12, a cytokine with a potent
antineoplastic activity, was associated with a better survival. A wider sample of patients is needed
to better clarify if our findings are intrinsically related to patients population or if they are simply
an epiphenomenon of disease progression.
Background
Renal cell carcinoma (RCC) is a chemoresistant disease
and also immunotherapy-based regimens are considered
of a modest efficacy [1]. In fact, metastatic RCC (MRCC)
has a poor prognosis with a median overall survival of
about one year until few years ago [2]. Recombinant Inter-
leukin-2 (IL-2) and interferon alpha (α-IFN) were the
most widely used cytokines in MRCC inducing objective
response rates from 15% to 20% as monotherapy or as
combined regimens [3,4]. The efficacy of adding chemo-
therapy to immunotherapy in MRCC remains questiona-
ble. In our experience, a very high percentage of response
was obtained with a bi-weekly regimen including subcu-
taneous IL-2, Vinorelbine and Gemcitabine [5]. Recently,
some multi-target oriented drugs have shown an impres-
sive activity in MRCC with a high percentage of partial
response and/or stable disease with a significant impact
on survival [6,7]. Nevertheless, immunotherapy remains
another important therapeutic option for these patients
thanks to its curative potential in some patients and its
capability to obtain very durable responses as demon-
strated by long-term follow-up. Therefore, the increasing
therapeutic options for RCC should be seen not as a com-
petition among the different treatments, but as an
expanding armamentarium available for these patients.
Since only a part of patients experienced therapeutic ben-
efit to the current treatments, several studies have
attempted to identify factors that may have an impact on
response and survival in MRCC patients. Some previously
published studies identified a number of clinical and
standard bio-humoral parameters correlated with a
poorer survival and predictive of rapid progression [8-11],
but at present data regarding basal cytokines profile in
MRCC are very few.
Cytokines regulate cellular immune interactions and are
produced by lymphocytes, monocytes, macrophages, and,
some cytokines, also by fibroblasts, neutrophils, endothe-
lial cells, or mast cells [12,13]. They play a crucial role in
the host's immune response by regulating the develop-
ment and function of a lot of biological compartments as
the immunological and angiogenic ones [14]. Normally,
cytokines are most commonly assessed at the macro-envi-
ronmental levels by measuring serum and plasma levels
or levels in the supernatant of in vitro-stimulated blood
cells; nevertheless, these data do not reflect their real work
in an in vivo micro-environmental contest [13]. Moreover,
a lot of sub-clinical situations and chronic co-morbidity
could influence cytokines profile in patients with meta-
static neoplasms. Since cytokines are released in a large
number of inflammatory, non-neoplastic conditions,
when detected in the serum of cancer patients, they can-
not be used as specific markers of neoplastic disease, but
rather as markers of the overall serological pattern of con-
comitant diseases.
No clear profile of serum cytokine has been identified yet
in the patients with metastatic tumours, and it does not
exit a clear cytokines cut-off between patients and health
subjects. Finally, it is not clear what are the levels of
cytokines able to discriminate normal and pathological
situation and what is the significance of cytokines modifi-
cations during the tumor progression or during some bio-
logical therapy such as IL-2 therapy. Finally, it is not clear
if different cytokine profiles are correlated with particular
clinical behaviors.
Our and other groups have recently demonstrated that C-
Reactive Protein (CRP) has a strong negative impact of
response and survival in MRCC [15]. In our previous
experience we analysed in the same population of the
present study, a list of clinical and serum parameters in
order to verify their prognostic and predictive significance.
In the univariate analysis, we found that a good PS (P =
0.0000), prior nephrectomy (P = 0.0001), disease free
interval (DFI) longer than 12 months (P = 0.0003), bone
disease site (P = 0.0013), low number of metastatic site (P
= 0.0449), normal albumin (P = 0.0001), low/normal
fibrinogen (P = 0.0140), low/normal LDH (P = 0.0430)
and low/normal CRP (P = 0.0000) were related to a better
survival; nevertheless in the multivariate analysis, only
CRP (P = 0.002) and DFI (P = 0.0497) were found to have
an independent role on survival. For this reason we also
included in the analysis of the present study these two sig-
nificant parameters.Journal of Translational Medicine 2007, 5:51 http://www.translational-medicine.com/content/5/1/51
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We analysed in 144 normal donors and in 55 patients
affected by MRCC treated with different regimens includ-
ing low dose subcutaneous IL-2, the basal levels of a panel
of cytokines particularly involved in the neoplastic pre-
gression processes (IL-1 beta, IL-6, IL-8, IL-10, IL-12, α-
TNF) and CRP in order to compare their profiles in the
two groups, and to verify their impact on patient response
and survival.
Methods
Patients and treatment
We analysed a total of 55 patients with MRCC of which we
had available serum. All patients were treated at the
Oncology Institute of Bari, Italy in three phase II studies
approved by the local ethics and carried out in the past 5
years. An histological proven diagnosis of RCC and an
adequate Eastern Cooperative Oncology Group (ECOG)
performance status (0–2) were also requested. Tumour
response was defined according to the WHO criteria. Data
from the three studies were pooled and than analysed.
Treatment consisted of low dose subcutaneous IL-2 alone
(15 patients), or IL-2 plus chemotherapy including Vin-
blastine (20 patients), or Gemcitabine plus Vinorelbine
(20 patients). The main characteristics of patients are
shown in Table 1.
Clinical results, irrespective of the regimen used, included
21% of complete plus partial response (CR + PR), 29% of
stable disease (SD) and 50% of progressive disease (PD).
Median overall survival for all patients was 9 months (1–
40 months), 15 months for CR + PR patients (4–40
months), 14 months for SD patients (2–36 months) and
6 months for PD patients (1–35 months), respectively.
Sample analysis
We analysed a panel of cytokines (IL-1b, IL-6, IL-8, IL-10,
IL-12 and TNF-α) both in patients population and healthy
donors constituted by individuals without inflammatory
and chronic diseases. This group was comparable with the
patients group regarding age, gender and race distribu-
tion. Moreover, in the patient group, we also included
CRP levels previously identified as a strong negative factor
of response and survival in MRCC [15].
Serum samples were obtained from patients on the day
prior to the beginning of treatment and stored at -80°C.
Serum samples were also obtained from a control popula-
tion of 144 healthy donors with comparable sex and age
distribution. Each sample was tested in a double aliquot
for each different cytokine. Informed consent was
obtained from all patients and control subjects.
Rate nephelometry was employed in the quantitative
determination of CRP (Beckman Coulter); normal range
considered has been < 0.8 mg/dl, IL-1 beta, IL-6, IL-8, IL-
10, IL-12, and alpha TNF serum levels were measured by
a powerful multiplexed assay combined with flow cytom-
etry using commercially available kits BD™ Human
Inflammation Cytometric Bead Array (CBA) and accord-
ing to the kit procedure (BD Biosciences Immunocytome-
try Systems and BD Bioscience Pharmigen). The
inflammation CBA assay, simultaneously quantifying IL-
1b, IL-6, IL-8, IL-10, IL-12p70, and TNF-a in a single sam-
ple, used 25 µl of serum sample. Incubation time was 6 h,
CBA beads were analyzed with a FACS Can flow cytometer
(BD Biosciences) and analyzed with the proprietary soft-
ware. The detection limit of kit was 0 pg/ml for all
cytokines.
We first evaluated cytokines levels both in patients popu-
lation and healthy donors. Results were expressed as per-
centage of detectable values and as median values in both
groups. Than, we divided our patients into two different
groups using the median values obtained from the control
group (above and below the median value of healthy
donors). The response rate and overall survival were ana-
lyzed in the two groups of patients.
Statistical analysis
Data were analyzed using the SPSS software package
(SPSS, Inc., Chicago, IL, USA). Statistical significance was
defined at p < 0.05 for univariate and multivariate analy-
ses. Standard curves were generated for each assay and
experimental values were computed by using a regression
analysis. Survival curves were traced according to Kaplan-
Maier and differences analyzed with log-rank test (level of
significance < 0.05. The t-test was used to compare the
basal levels of bio-humoral parameters (normal range ver-
sus abnormal range) with respect to the clinical response.
Table 1: Patients characteristics
Characteristics
Median ECOG PS (range; PS 0/1/2) 1 (0–2; 10/40/5)
Median age (range) 62 (27–82)
Sex
men (%) 35 (64%)
woman (%) 20 (36%)
Disease site (%)
Brain 2 (4%)
Bone 11 (20%)
Liver/viscera 23 (43%)
Soft tissue/lung 18 (33%)
Pts metastatic sites (%)
11 6  ( 3 0 % )
> 1 39 (70%)
Median Disease Free Interval (range) 4 (0–240)
Nephrectomy (%)
Yes 50 (91%)
No 5 (9%)Journal of Translational Medicine 2007, 5:51 http://www.translational-medicine.com/content/5/1/51
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As regards the response analysis, 95% confidence interval
(95% CI) of response rate was calculated, and comparison
between groups was assessed using chi-square's test. We
used univariate analysis to evaluate the relation between
survival and response to treatment with respect to the
baseline cytokines and CRP levels. The cytokines and CRP
were included in the model as a dichotomous variables in
two categories: above and below the median values of
healthy donors for cytokines and inferior or superior to
normal value for CRP. We used the median rather than
the mean of variables considered in statistical tests
because of their not gaussian distribution.
All the parameters resulted significant in the univariate
analysis were considered for the multivariate analysis. The
Cox proportional hazards model was used in multivariate
analyses to study the prognostic impact of the different
variables on survival. From an initial model, using a back-
ward selection procedure, a final parsimonious model
was obtained. Results of these analyses were reported in
risk ratios of dying with 95% confidence intervals (CIs)
[16]. We also performed a no-parametric test of the
median to compare median normal value of cytokines of
healthy donors with respect to those of the patients.
Results
We analysed the cytokines levels of 144 healthy donors
and of 55 patients with MRCC. When we compared the
cytokines levels of healthy donors with those of patients,
we found undetectable levels of IL-1b in the 0.1% of
healthy donors compared to 0% of patients (p = 0.131);
IL-6 was undetectable in the 27% of healthy donors com-
pared to 24% of patients (p = 0.858); IL-8 was undetecta-
ble in the 41% of healthy donors compared to 28% of
patients (p = 1); IL-10 was undetectable in the 56%
healthy donors compared to 19% of patients (p < 0.001);
IL-12 was undetectable in the 32% of healthy donors
compared to 0.1% of patients (p = 0.003); TNF-α was
undetectable in the 64% of healthy donors compared to
19% of patients (p < 0.001).
We also expressed our data as median values in both
healthy donors and patients group. Data regarding the
donors are as follow: IL1beta = 27.8 pg/ml (range, 0 to
514.1 pg/ml), IL6 = 4 pg/ml (range, 0 to 85.7 pg/ml), IL8
= 50.7 pg/ml (range, 0 to 570.1 pg/ml), IL10 = 0 pg/ml
(range, 0 to 21.3 pg/ml), IL12 = 5.2 pg/ml (range, 0 to
126.7 pg/ml), alpha TNF = 0 pg/ml (range, 0 to 45.8 pg/
ml). In the patient group, the median values were: IL1beta
= 22.25 pg/ml (range, 0 to 779.8 pg/ml), IL6 = 6.1 pg/ml
(range, 0 to 136.3 pg/ml), IL8 = 40.3 pg/ml (range, 8.1 to
445.3 pg/ml), IL10 = 3.35 pg/ml (range, 0 to 49 pg/ml),
IL12 = 4.3 pg/ml (range, 0 to 435.15 pg/ml), alpha TNF-
α = 2.05 pg/ml (range, 0 to 15.7 pg/ml). When we com-
pared the median values of cytokines of the 144 healthy
donors with those of the 55 patients, we found a signifi-
cant difference just for TNF-α (p < 0.001), IL-10 (p <
0.001) and IL-6 (p = 0.047); IL-12 showed a difference
near the statistical significance (p = 0.074) (Fig. 1).
Table 2 summarizes the correlation between the cytokines
and survival. In univariate analysis, higher values of IL-6
were found to correlate with a worse survival with respect
to lower values: 9 months and 25 months respectively (p
= 0.0295). Also the CRP and IL-8 had the same capability
to discriminate patients with a different survival as IL-6:
higher levels of CRP were correlated with a poorer survival
(8 months with respect to 31 for lower levels) (p <
0.0001); higher levels of IL-8 were also correlated with a
poorer survival (9 months with respect to 17 months for
lower levels) (p = 0.0371). Regarding IL-12, a better sur-
vival was correlated with higher levels of this cytokine (25
months) with respect to lower levels (15 months), but the
difference was not significant months (p = 0.0882). Con-
versely, the different levels of IL-1b, IL-10 and TNF-α are
not able to discriminate patients with different survival.
Figures 2 and 3 summarize the survival curves of patients
according to significant cytokines (IL-6, IL-8 and IL-12)
and CRP.
The impact of baseline cytokines on response was insig-
nificant. Only higher levels of CRP were strongly corre-
lated with a worse response (p < 0.001). The majority of
progressive patients showed high value of CRP (73.1%;
95% CI, 56% to 89%) compared to patients with PR+CR/
No-parametric test comparing the median levels of cytokines  in healthy donors and patients Figure 1
No-parametric test comparing the median levels of cytokines 
in healthy donors and patients.
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SD (26.9% with value above the normal) (p = 0.003).
Moreover, when we carried out a chi-square test on asso-
ciations between cut-off variables, we just found an asso-
ciation between CRP and IL-6 (p = 0.009), and CRP and
IL-10 (p = 0.038).
We also carried out a multivariate analysis on the 55
patients considering the panel of cytokines and CRP,
using a backward selection procedure. At the final parsi-
monious model, only CRP (p = 0.0035), and IL-12 (p =
0.0371) were found to have independent impact on sur-
vival; in addition IL-6 showed a borderline value (p =
0.0792) (Table 3).
Discussion
Immunotherapy remains one of the therapeutic options
for patients with MRCC. In particular, IL-2 have demon-
strated to obtain very durable responses and stable disease
in some patients. Nevertheless, the antineoplastic mecha-
nisms of IL-2 and its effects on peripheral blood mononu-
clear cells and T cell subsets are only partially known
[2,3,17,18].
The evaluation of cytokines in the serum of neoplastic
patients and in normal subjects is arduous because of a
series of concomitant sub-clinical situations and acute or
chronic co-morbidities. Moreover, it does not exist a clear
cytokine cut-off between patients and healthy subjects,
and it is also unclear what are the levels of cytokines able
to discriminate normal and pathological conditions [14].
Available data on basal cytokine levels in MRCC are very
few. No clear profile of serum cytokines has been identi-
fied yet in these patients population and even less is
known about cytokine behaviour during treatment [18].
We evaluated a panel of basal cytokines more commonly
involved in the tumor control and progression (IL-1 beta,
IL-6, IL-8, IL-10, IL-12, TNF-α) both in 144 healthy
donors and in 55 patients affected by MRCC treated with
IL-2 based regimens. Because we and other group have
recently demonstrated that C-Reactive Protein (CRP) has
a strong negative impact of response and survival in
MRCC [15], we also included the CRP levels among the
parameters analysed in the present study.
It is known that a possible imbalance in the type1 (IL-12
and Interferon-γ), and type 2 cytokine (IL-6, IL-10) pat-
tern has been postulated in neoplastic patients [18]. In
particular, IL-6 is a multipotent cytokine exerting numer-
ous biological activity. It regulates the proliferation and
differentiation of immunocompetent cells including T-
and B-lymphocytes, NK cells, normal hematopoietic pro-
genitors, epithelial and neural cells. IL-6 is also produced
by several epithelial cancer cell lines and it may act as pos-
sible growth factors in advanced melanoma. IL-6 is also
able to inhibits cell-cell adhesion and to promote spread-
ing of cancer cells and to inhibit T-cell proliferative
response. IL-6 is also a potent pro-inflammatory cytokine.
It acts as an endogenous pyrogen and induces the expres-
sion of the acute phase protein genes including the CRP
gene. Finally, IL-6 blocks apoptosis induced by p53,
TGFβ, and several chemotherapeutic agents. IL-6 is usu-
Table 2: Results of the univariate analysis testing the panel of cytokines and CRP
Parameters % Pts Median Survival (CI) (mos) p Value (log rank)
IL-Iβ:
< 27,8 pg/ml 57 11 (5.05–16.95) 0.1761
> 27,8 pg/ml 43 24 (14.20–33.80)
IL-6:
< 4 pg/ml 40 25 (11.82–38.18) 0.0295
> 4 pg/ml 60 9 (5.44–12.56)
IL-8:
< 50,7 pg/ml 62 17 (0.00–34.06) 0.0370
> 50,7 pg/ml 38 9 (0.00–23.16)
IL-10:
< 0 pg/ml 19 19 (1.82–36.18) 0.3954
> 0 pg/ml 81 15 (7.04–22.96)
IL-12:
< 5,2 pg/ml 64 15 (6.93–23.07) 0.0882
> 5,2 pg/ml 36 25 (19.87–30.13)
TNF-α:
< 0 pg/ml 19 7 (0.80–13.20) 0.1159
> 0 pg/ml 81 20 (10.56–29.44)
CRP:
< 0,8 mg/dl 46 31 (21.29–40.71) < 0.0001
> 0,8 mg/dl 54 8 (5.68–10.32)
Abbreviations: CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factorJournal of Translational Medicine 2007, 5:51 http://www.translational-medicine.com/content/5/1/51
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ally co-expressed together to IL-10, another potent sup-
pressor of immune functions including antigen
presentation, cytokine production, macrophage activa-
tion, and antigen-specific T-cell activation [18]. IL-10
downregulates class II MHC expression (immunosuppres-
sive activity) and inhibits the production of proinflamma-
tory cytokines by monocytes. Higher levels of IL-10 have
been found in metastitic melanoma patients with respect
to healthy donors. Nevertheless, the role of both these
cytokine is complex and not completely clear yet. In
experimental model both IL-6 and IL-10 exert antitumor
effects in mice and enhance the major histocompatibility-
restricted and non-restricted cytotoxic activity. IL-8 and IL-
12 probably play a less relevant role in neoplastic diseases.
IL-8 is able to induces tumoral cells migration and inhib-
its the lymphocytes tumor infiltration. Moreover, its sero-
logical levels correlate with the tumor load. IL-12 induces
a Th1-type response and tumor rejection. It is also able to
inhibit angiogenesis induced by tumor cell lines [12-
14,18]. CRP seems mainly to reflect IL-6 secretion. More-
over, elevated pretreatment values are frequent in
advanced cancer patients with poor prognostic character-
istics, such as cachexia. Finally, pretreatment high levels of
CRP predict both the lack of IL-2 activity on tumour objec-
tive response and its efficacy on overall survival in meta-
static cancer patients [15].
Table 3: Final multivariate model
Variables HR 95% CI p
IL12 (< 5.2 vs > 5.2 g/ml) 0.3525 0.1323–0,9394 0.0371
IL6 (< 4 vs > 4 pg/ml) 2.3115 0.9070–5.8911 0.0792
IL10 (< 0 vs > 0 pg/ml) 3.0490 0.7458–12.4647 0.1207
CRP (< 0.8 vs > 0.8 mg/dl) 4.0361 1.5801–10.3099 0.0035
Overall survival in patients according to significant univariate  analysis parameters Figure 2
Overall survival in patients according to significant univariate 
analysis parameters. A, CRP < 0.8 VS > 0.8 mg/dl. B, IL-6 < 4 
vs > 4 pg/ml.
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Overall survival in patients according to significant univariate  analysis parameters Figure 3
Overall survival in patients according to significant univariate 
analysis parameters. A, IL-8 < 50.7 vs > 50.7 pg/ml. B, IL-12 < 
5.2 vs > 5.2 pg/ml.
A) 
0
10
20
30
40
50
60
70
80
90
100
0 1 02 03 04 0
Months
O
v
e
r
a
l
l
 
S
u
r
v
i
v
a
l
B) 
0
10
20
30
40
50
60
70
80
90
100
01 0 2 0 3 0
Months
O
v
e
r
a
l
l
 
S
u
r
v
i
v
a
l
IL-8 < 50.7 pg/ml
IL-8 > 50.7 pg/ml
p= 0.0371
IL-12 >5.2 pg/ml
IL-12 < 5.2 pg/ml
p= 0.0882Journal of Translational Medicine 2007, 5:51 http://www.translational-medicine.com/content/5/1/51
Page 7 of 7
(page number not for citation purposes)
Our results suggest that cytokine profile greatly differs
between patient population and healthy control. We
found a higher percentage of individuals with undetecta-
ble levels of cytokines in healthy donors with respect to
patients (TNF-α, p < 0.001; IL-10, p < 0.001; IL-12, p =
0.003). When we analysed our data as median values, in
patient population we found higher values of TNF-α (p <
0.001), IL-10 (p < 0.001) and IL-6 (p = 0.047) and lower
values of IL-12 (p = 0.074), IL-1β (p = 0.558) and IL-8 (p
= 0.501) compared with healthy donors (Fig. 1). No cor-
relation was found between the baseline cytokines and
response, except for CRP which was inversely correlated
with a better response. Regarding data on survival, higher
levels of IL-6 (p = 0.0295) and IL-8 (p = 0.0371) and lower
levels of IL-12 (p = 0.0882) was associated with a worse
survival. Nevertheless, in a multivariate analysis only IL-
12 (p = 0.0371; HR 0.3) and CRP (p = 0.0035; HR 4.0)
had an independent impact on survival, while IL-6 show-
ing a borderline value (p = 0.0792; HR 2.3).
Moreover, in this study we confirmed that both high lev-
els of CRP and IL-6 are correlated with a poorer survival in
MRCC patients (p < 0.001 for CRP and p = 0.0295 for IL-
6) with an independent role (p = 0.0035 for CRP and p =
0.0792 for IL-6) and a high grade of association (p =
0.009).
Our findings suggest that probably the pattern of
cytokines does not reflect just an inflammatory status, but
it is indicative of a particular biological pattern of
advanced neoplastic disease. In fact, the patient with a
worse survival showed not only higher levels of IL-10, IL-
6 and TNF-α, which are notoriously involved in disease
progression and in immunosoppressive mechanisms, but
also lower levels of IL-12 which has an antineoplastic
potential [13,14,18]. These observations suggest that a
degree of immunological imbalance exists in the patient
group. Nevertheless, because of the small number of sam-
ple it is arduous to interpret these results and to draw
definitive conclusions. A wider sample of patients is
needed to better clarify if our findings are intrinsically
related to the patients population or if they are simply an
epiphenomenon of disease progression.
In conclusion, we observed that in addition to CRP, also
high level of immunosuppressive cytokines such as IL-6
and IL-8, and low level of IL-12, a cytokine with a potent
antineoplastic activity, correlated with a poorer survival in
MRCC patients. These findings may help to better define
a baseline cytokine pattern for this setting of patients.
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